著者

大内 隆宏 平田 一耕 村山 和真 舟越 亮寛

出版者

一般社団法人 日本医薬品情報学会

雑誌

医薬品情報学 (ISSN:13451464)

巻号頁・発行日

vol.24, no.4, pp.179-186, 2023-02-28 (Released:2023-04-07)

参考文献数

17

---

Objective: The success rate of third-line treatment for Helicobacter pylori (H. pylori) infection has been reported to depend on the use of antibacterial agents, potassium-competitive acid blockers, and proton pump inhibitors. However, there is insufficient information on the success rate of H. pylori treatment due to the differences in the clinically used drugs. Here, the factors influencing the success rate of third-line treatment for H. pylori infection was investigated.Methods: Patients aged 20 years or older, who had received third-line treatment for H. pylori infection from January 2013 to December 2021 at the Kameda Medical Center were included. The exclusion criteria were as follows: patients with unknown treatment results and discontinuation of treatment. The primary endpoint was treatment success rate, based on the differences in the treatment regimen and drug choice, which was retroactively investigated from medical records. Confounding factors were adjusted by multivariate logistic regression analysis.Results: Treatment regimens containing sitafloxacin resulted in higher treatment success rates (p<0.05). Multivariate logistic regression analysis showed that the administration of sitafloxacin was the only statistically significant factor influencing treatment success. However, vonoprazan also tended to influence treatment success.Conclusion: Treatment with sitafloxacin and vonoprazan increases the success rate of third-line treatment against H. pylori infection.

著者

平田 一耕 舟越 亮寛

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.143, no.11, pp.941-949, 2023-11-01 (Released:2023-11-01)

参考文献数

23

---

Inflammatory bowel disease (IBD) is an autoimmune disease that inflames the intestinal tract and reduces patient quality of life. In recent years, prescriptions of biologics and Janus kinase inhibitors have made outpatient pharmacists indispensable to clinics and hospitals. Therefore, we retrospectively investigated the effectiveness of immunopharmacist outpatient services in treating IBD. The survey spanned between January 2019 and December 2020 and included patients who had visited an IBD-specialized outpatient clinic. The endpoints were the number of pharmaceutical and accepted interventions, improvement rates, and cost-effectiveness of the pharmacist outpatient services. The definition of pharmaceutical intervention involves the pharmacist outpatient clinic, which refers to the number of prescription proposals made to doctors, and the dispensing room, which refers to the number of inquiries made to doctors. The survey included 139 patients, and 579 assessments were performed in the pharmacist outpatient clinic. Out of 352 pharmaceutical interventions by the outpatient pharmacist group, 341 (96.9%) were accepted by physicians. Similarly, out of 74 pharmaceutical interventions by the dispensing group, 54 (73.0%) were accepted by physicians (p<0.0001). The overall improvement rate of pharmaceutical interventions was 93.5%. The immunopharmacist outpatient clinic was found to be cost-effective, with an estimated value of 44068000 yen. In IBD outpatient services, clinical pharmacists and physicians are integral members of the medical care team and have a positive impact on drug treatment outcomes.